Cantor Fitzgerald Thinks Revance Therapeutics’ Stock is Going to Recover


Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on Revance Therapeutics (NASDAQ: RVNC) today and set a price target of $50. The company’s shares opened today at $23.09, close to its 52-week low of $22.25.

Chen commented:

“We reiterate our Overweight rating. We expect upward earnings revisions to levels not reflected in sell-side consensus expectations to drive the shares higher. These could come from positive news flow for Revance’s key programs in development. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $50 and Overweight rating.”

According to TipRanks.com, Chen is a 5-star analyst with an average return of 11.6% and a 40.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.

Revance Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $49.

See today’s analyst top recommended stocks >>

The company has a one-year high of $37.45 and a one-year low of $22.25. Currently, Revance Therapeutics has an average volume of 246.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts